Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Scottsdale, Arizona 85254


The purpose of this study is to determine if near infrared light therapy is effective in decreasing pain in patients with painful peripheral neuropathy.

Study summary:

Pain is a very common symptom, between 65-80%, in patients with peripheral neuropathy. This study is designed to evaluate the effectiveness of near infrared photoenergy therapy in the treatment of pain in axonal peripheral neuropathy. This will be compared with a placebo(sham) device. Study subjects will receive treatment with the device or the placebo device 3 times per week for 4 weeks. Response will be measured during and after the treatment period.


Inclusion Criteria: - Adults ages 18-85; able to give informed consent - Documented painful, distal peripheral neuropathy of idiopathic cause, or related to impaired glucose tolerance or diabetes mellitus. - Neuropathy documented by one of the following studies: nerve conduction studies and needle electromyography (EMG); quantitative sensory testing of the foot with CASE IV; quantitative sudomotor axon reflex test (QSART); neurology specialty examination; and neuropathy impairment score (NIS) of less than 25. - Stable pharmacotherapy for neuropathic pain for at least two weeks. - Optimal pharmacotherapy has been achieved. - Subjects cannot be on COX 2 inhibitors - VAS of greater than or equal to 4/10 - Subject has provided written informed consent - Not currently using transcutaneous electrical nerve stimulation (TENS) - Not currently receiving acupuncture Exclusion Criteria: - Pregnant or likely to become pregnant - Current diagnosis of cancer - Neuropathy impairment score (NIS) of greater than 25. - Diagnosis of severe neuropathy of known etiology for which specific treatment is available (i.e., acute and chronic inflammatory polyradiculoneuropathies, vasculitis, B 12 deficiency). - Unstable diabetes mellitus defined as a HbA1c greater than 9%, and/or 10% of fasting blood sugars greater than 300 mg/dl for the week prior to enrollment.



Primary Contact:

Principal Investigator
Matthew A Butters, MD
Mayo Clinic

Backup Contact:


Location Contact:

Scottsdale, Arizona 85254
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.